Galectin names Thomas McGauley acting CFO
This article was originally published in Scrip
Galectin Therapeutics, a company developing therapies for cancer and fibrotic disease, has appointed Thomas McGauley acting chief financial officer replacing Anthony Squeglia. Mr McGauley will serve in this role until 30 September 2012 when a permanent CFO can be found. He has been the company's director of finance and accounting since 2009, and until 2010 was director of financial reporting at deCODE genetics. He previously worked in public accounting for companies including PricewaterhouseCoopers, where he specialised in life sciences.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.